Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jan-Feb;15(1):14-18.
doi: 10.1016/j.prro.2024.10.014. Epub 2024 Nov 9.

Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy

Abigail Pepin  1 , Ana Kiess  2 , J Nicholas Lukens  1 , Philipose Mulugeta  3 , Neil K Taunk  4
Affiliations
Case Reports

Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy

Abigail Pepin et al. Pract Radiat Oncol. 2025 Jan-Feb.

Abstract

Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with 177Lu-PSMA-617. Although 177Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical lumen of the acinar epithelium. Xerostomia resulting from the use of radioligand therapy is common. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 2 dry mouth event after administration of 177Lu-PSMA-617. The patient was managed with oral hygiene and xerostomia mitigation strategies using oral rinses.

PubMed Disclaimer

Conflict of interest statement

Disclosures Abigail Pepin discloses travel support through the National Cancer Comprehensive Network. Ana Kiess discloses clinical trial support from Bayer, Novartis, Merck, and Lantheus. Ana Kiess serves as an unpaid consultant/advisor for Novartis and an unpaid educational speaker for POINT. J Nicholas Lukens serves on the NCCN panel for nonmelanoma skin cancer and serves on the ASTRO educational committee (head and neck track). J Nicholas Lukens also serves on the data safety and monitoring board for Proton Therapy for Infants and Young Children with Brain Tumors. Philipose Mulugeta discloses travel support from Telix Pharmaceuticals. Philipose Mulugeta participates as part of the CTMRS at Abramson Cancer Center. Neil K. Taunk discloses contract grants through Varian Medical Systems. Neil K. Taunk endorses consulting fees through Boston Scientific, Varian Medical Systems, Seagen, and Point BioPharma. Neil K. Taunk discloses support from Telix Pharmaceuticals and Boston Scientific. Neil K. Taunk discloses participation with NCI Solid Tumor DSMB, Boston Scientific, and Varian Medical Systems.

Publication types

MeSH terms

LinkOut - more resources